Selling AI to Indian hospitals is not like selling it anywhere else. The purchasing decision rarely sits with one person. A typical mid-size hospital group will involve the CMO, the CFO, the IT head, and often the hospital's board or a founder-family member. Getting to a signed order means winning trust at each layer — and each layer has a different definition of trust.
For clinicians, trust means clinical validation in an Indian patient context. Datasets trained on Western populations, even excellent ones, are viewed with legitimate scepticism. For CIOs, trust means integration with existing HIS systems like Insta HMS or Marg, which are deeply embedded and will not be replaced. For CFOs, trust means a pricing model that accounts for the reality that Indian healthcare margins are thin and patient volumes vary dramatically across tier-1 and tier-2 cities.
The Pharmaceutical Landscape
The pharma side is different again. Large Indian pharma companies — Sun, Cipla, Dr. Reddy's — are increasingly sophisticated AI buyers. They are looking for AI that accelerates drug discovery, optimises clinical trial recruitment, and improves supply chain predictability. The decision-making here is faster and more centralised than in hospitals. The challenge is that their global counterparts are also knocking on the same doors. Local credibility matters enormously.
(Add your extended analysis here...)